Table 3 Cases where ALTO is clinically superior or inferior to each indicated strategy
From: Long range personalized cancer treatment strategies incorporating evolutionary dynamics
Strategy | Inferior 2 | Superior 2 | Inferior 3 | Superior 3 |
|---|---|---|---|---|
Strategy 0 (Current precision medicine) | 5 (0.003 %) | 176718 (99.997 %) | 1808 (0.2 %) | 898155 (99.8 %) |
Single step strategy 2.2 | 5 (0.08 %) | 6378 (99.92 %) | 5631 (14.5 %) | 33093 (85.5 %) |
Multi-step strategy 2.2 | 5 (2.7 %) | 179 (97.3 %) | 6247 (33.1 %) | 12608 (66.9 %) |
ALTO-SMO | 5 (0.02 %) | 32621 (99.98 %) | 6313 (10.4 %) | 54374 (89.6 %) |